Lanatoside C

Lanatoside C

File:Isolanid.png
Systematic (IUPAC) name
(3β,5β,12β)- 3-{[β-D- glucopyranosyl- (1→4)- 3-O-acetyl- 2,6-dideoxy- β-D-ribo- hexopyranosyl- (1→4)- 2,6-dideoxy- β-D- ribo- hexopyranosyl- (1→4)- 2,6-dideoxy- β-D- ribo- hexopyranosyl]oxy}- 12,14-dihydroxycard- 20(22)- enolide
Identifiers
CAS Number	17575-22-3
ATC code	C01AA06 (WHO)
PubChem	CID 3879
Synonyms	[6-[6-[6-[[12,14-dihydroxy- 10,13-dimethyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthren- 3-yl]oxy]- 4-hydroxy- 2-methyloxan- 3-yl]oxy- 4-hydroxy- 2-methyloxan-3-yl]oxy- 2-methyl- 3-[3,4,5-trihydroxy- 6-(hydroxymethyl)oxan-2-yl]oxyoxan- 4-yl] acetate
Chemical data
Formula	C49H76O20
Molar mass	985.116 g/mol[[]]

Lanatoside C (or isolanid) is a cardiac glycoside, which can be used by the intravenous route. It is marketed as Cedilanide in Brazil by Novartis. Its main indications are rapid responde atrial fibrilation and paroxistic supraventricular tachycardia.